Bellevue Group’s Array Biopharma Inc ARRY Stock Holding History

Bellevue Group’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-48,200	Closed	-$1.18M	–	220
2019 Q1	$1.18M	Buy	+48,200	New	+$1M	0.06%	122

Other funds holding ARRY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bellevue Group's ARRY Position: Q2 2019 in Review

Bellevue Group sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 48,200 shares — an estimated $1.18M sold.

Bellevue Group first reported a position in ARRY in Q1 2019 and held it in 1 quarter. The position peaked at $1.18M in Q1 2019. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

Bellevue Group reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
Bellevue Group sold 48,200 Array Biopharma Inc shares in Q2 2019, an estimated $1.18M.
Bellevue Group first reported a position in Array Biopharma Inc in Q1 2019 and held it in 1 quarter.
Bellevue Group's Array Biopharma Inc position peaked at $1.18M in Q1 2019.
318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.